CSFβ-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease:: The effect of APOE ε4 allele

被引:19
|
作者
Smach, Mohamed Ali [1 ]
Charfeddine, Bassem [1 ]
Lammouchi, Turkia [2 ]
Harrabi, Imed
Ben Othman, Leila [1 ]
Dridi, Hedi [1 ]
Bennamou, Soufien [2 ]
Limem, Khalifa [1 ]
机构
[1] Fac Med Sousse, Dept Biochem, Sousse, Tunisia
[2] Sahloul Hosp, Dept Neurol, Sousse 4054, Tunisia
关键词
Alzheimer's disease; t-tau; beta-amyloid; apolipoprotein E; risk factor;
D O I
10.1016/j.neulet.2008.05.076
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. An accurate, convenient and objective test to detect AD is urgently needed for efficient drug development and effective clinical use of emerging therapies. The aim of the present work is to investigate the usefulness of cerebrospinal fluid (CSF) beta-amyloid protein (A beta 1-42) and total tau protein (t-tau) analyses in the diagnosis of AD and whether apolipoprotein E (ApoE) epsilon 4 allele is a factor for AD affecting Tunisian people. A beta 1-42 and t-tau levels were measured in CSF from AD patients (n = 73), non-Alzheimer dementia (nAD, n = 35) and healthy controls (HC, n = 38) by sandwich enzyme-linked immunosorbent assay. A beta 1-42 levels were decreased and t-tau increased in AD patients. The combination 4A beta 1-42 and t-tau at baseline yielded a sensitivity of 87.4% for detection of AD. The specificities were 97.3% for controls and 82.7% for other dementia. The ApoE epsilon 4 allele frequency (29.5%) was significantly higher in the AD patients than in the nAD patients (17.1%) or in the control groups (9.5%). AD patients carrying ApoE epsilon 4 allele had lower A beta 1-42 (p < 0.001) levels than those without a epsilon 4 allele. The combination of t-tau and A beta 1-42 is a robust and reliable assay that may be useful in discriminating cases at risk for AD such as ApoE epsilon 4 allele carriers from nAD patients or from age-matched control subjects. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 50 条
  • [1] CSF tau and amyloid β1-42 (Aβ42) as possible biomarkers of Alzheimer disease
    Ravid, R
    Kamphorst, W
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S298 - S298
  • [2] Cerebrospinal fluid β-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease:: The effect of APOE ε4 allele
    Sunderland, T
    Mirza, N
    Putnam, KT
    Linker, G
    Bhupali, D
    Durham, R
    Soares, H
    Kimmel, L
    Friedman, D
    Bergeson, J
    Csako, G
    Levy, JA
    Bartko, JJ
    Cohen, RM
    [J]. BIOLOGICAL PSYCHIATRY, 2004, 56 (09) : 670 - 676
  • [3] Relationship between apoE genotype and CSF β-amyloid (1-42) and tan in patients with probable and definite Alzheimer's disease
    Tapiola, T
    Pirttilä, T
    Mehta, PD
    Alafuzoff, I
    Lehtovirta, M
    Soininen, H
    [J]. NEUROBIOLOGY OF AGING, 2000, 21 (05) : 735 - 740
  • [4] Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
    Schoonenboom, NSM
    Pijnenburg, YAL
    Mulder, C
    Rosso, SM
    Van Elk, EJ
    Van Kamp, GJ
    Van Swieten, JC
    Scheltens, P
    [J]. NEUROLOGY, 2004, 62 (09) : 1580 - 1584
  • [5] Stability of CSF β-amyloid1-42 and tau levels by APOE genotype in Alzheimer patients
    Huey, Edward D.
    Mirza, Nadeem
    Putnam, Karen T.
    Soares, Holly
    Csako, Gyorgy
    Levy, James A.
    Copenhaver, Brittany
    Cohen, Robert M.
    Sunderland, Trey
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 22 (01) : 48 - 53
  • [6] Advances in the development of biomarkers for Alzheimer's disease -: From CSF total tau and amyloid-(β1-42) proteins to phosphorylated tau and amyloid-β-antibodies
    Hampel, H
    Teipel, S
    Faltraco, F
    Brettschneider, S
    Goernitz, A
    Buerger, K
    Moeller, HJ
    [J]. MOLECULAR NEUROBIOLOGY OF ALZHEIMER DISEASE AND RELATED DISORDERS, 2004, : 134 - 156
  • [7] Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease
    Pottiez, Gwenael
    Yang, Li
    Stewart, Tessandra
    Song, Ning
    Aro, Patrick
    Galasko, Douglas R.
    Quinn, Joseph F.
    Peskind, Elaine R.
    Shi, Min
    Zhang, Jing
    [J]. JOURNAL OF PROTEOME RESEARCH, 2017, 16 (03) : 1228 - 1238
  • [8] Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease?
    Kapaki, E
    Kilidireas, K
    Paraskevas, GP
    Michalopoulou, M
    Patsouris, E
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (03): : 401 - 403
  • [9] Interrelations between CSF Soluble AβPPβ, Amyloid-β 1-42, SORL1, and Tau Levels in Alzheimer's Disease
    Alexopoulos, Panagiotis
    Guo, Liang-Hao
    Tsolakidou, Amalia
    Kratzer, Martina
    Grimmer, Timo
    Westerteicher, Christine
    Jiang, Meizi
    Bujo, Hideaki
    Diehl-Schmid, Janine
    Kurz, Alexander
    Perneczky, Robert
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2012, 28 (03) : 543 - 552
  • [10] Total-tau, Aβ1-42 and Ubiquitin in CSF in the diagnosis of Alzheimer disease
    Iqbal, K
    [J]. EUROPEAN PSYCHIATRY, 2002, 17 : 76S - 76S